The BCG vaccine, originally developed for tuberculosis, has been shown in a European double-blind randomised clinical study to cut respiratory infections among the elderly by 75%, writes MedicalBrief. Its effect on COVID-19 patients requires further research, according to the results published in Cell this week.
The BCG vaccine, an old treatment originally developed for tuberculosis, has a broad, stimulating effect on the immune system. Frequently given to children, in this clinical study, a collaboration between Radboud University Medical Centre in the Netherland and the National and Kapodistrian University of Athens, it was shown that elderly people also benefit from it, says Redboud in a release.
Prof Mihai Netea, of Radboud’s department of experimental internal medicine, is conducting research into trained immunity, the protective effect against various infections by the BCG vaccine. Says Netea: “Two years ago we started the ACTIVATE study, with the aim of showing whether BCG vaccination could protect against infections in vulnerable elderly people. Patients over 65 years of age who were admitted to hospital were randomised to receive BCG or placebo vaccination at their discharge. We followed them for a year to see if BCG could protect them against a broad range of infections.”
The ACTIVATE study had already started before the corona pandemic. 198 elderly people were given either a placebo or a BCG vaccine upon discharge from the hospital. The last follow-up was scheduled for August 2020, but due to the arrival of COVID-19, the researchers looked at the preliminary results, published today in Cell.
There was a noticeable difference: in the placebo group, 42.3% of the elderly developed an infection, while this was the case in only 25% of the BCG group. It also took longer: the BCG-vaccinated participants had their first infection on average 16 weeks after vaccination, compared to 11 weeks for the placebo group. There was no difference in side effects.
Professor Evangelos J Giamarellos-Bourboulis, co-coordinator of the study at the 4th department of internal medicine at ATTIKON University Hospital: “In addition to the clear effect of BCG vaccination on infections in general, the most important observation was that BCG could mainly protect against respiratory infections: BCG-vaccinated elderly people had 75% fewer respiratory infections than the elderly who received placebo.”
Although most protection seems to have been against respiratory infections of (probably) viral origin, whether or not BCG also works against COVID-19 has not yet been demonstrated, due to the low prevalence of COVID-19 in this study. The study does show that the BCG vaccination is safe to give to the elderly, and that it can protect them against various infections. Several studies are underway that look specifically at the effects of BCG on COVID-19. Only these follow-up studies can provide clarity as to whether BCG vaccination can also protect against infections with the new coronavirus.
Not yet available online
Evangelos J Giamarellos-Bourboulis, Maria Tsilika, Simone Moorlag, Nikolaos Antonakos, Antigone Kotsaki, Jorge Domínguez-Andrés, Evdoxia Kyriazopoulou, Theologia Gkavogianni, Maria-Evangelia Adami, Georgia Damoraki, Panagiotis Koufargyris, Athanassios Karageorgos, Amalia Bolanou, Hans Koenen, Reinout van Crevel, Dionyssia-Irene Droggiti, George Renieris, Antonios Papadopoulos, Mihai G Netea
Cell abstract (journal pre-proof)
See also from MedicalBrief archives:Global review of BCG vaccine protection from severe COVID-19